Abstract
Contrast induced nephropathy (CIN) is a well-known and serious complication in patients with chronic renal insufficiency undergoing coronary angiography or interventions. CIN is associated with significant morbidity and mortality. This complication results in prolonged hospital stay and substantially increases the cost of medical care. Various therapeutic measures have been evaluated for the prevention of CIN. Peri-procedural saline hydration, use of low osmolality contrast agents and limiting the amount of contrast administered are the preferred methods. In recent years, the efficacy of prophylactic hemofiltration and several pharmacological agents, including low dose dopamine, theophylline, Nacetylcysteine, and fenoldopam have been evaluated in randomized controlled trials. Conflicting results, rather than convincing conclusions, were observed in the studies of most of these agents. Meta-analysis suggested that the use of Nacetylcysteine and theophylline may be able to prevent the decline of renal function after contrast exposure. This review provides an update on the recent studies in this subject as well as a critical analysis on how available evidence could be translated to daily clinical practice.
Keywords: Prevention, contrast induced nephropathy
Current Drug Therapy
Title: Prevention of Contrast Induced Nephropathy
Volume: 2 Issue: 1
Author(s): Jeffrey W.H. Fung, Cheuk C. Szeto, Leo C.C. Kum and Cheuk M. Yu
Affiliation:
Keywords: Prevention, contrast induced nephropathy
Abstract: Contrast induced nephropathy (CIN) is a well-known and serious complication in patients with chronic renal insufficiency undergoing coronary angiography or interventions. CIN is associated with significant morbidity and mortality. This complication results in prolonged hospital stay and substantially increases the cost of medical care. Various therapeutic measures have been evaluated for the prevention of CIN. Peri-procedural saline hydration, use of low osmolality contrast agents and limiting the amount of contrast administered are the preferred methods. In recent years, the efficacy of prophylactic hemofiltration and several pharmacological agents, including low dose dopamine, theophylline, Nacetylcysteine, and fenoldopam have been evaluated in randomized controlled trials. Conflicting results, rather than convincing conclusions, were observed in the studies of most of these agents. Meta-analysis suggested that the use of Nacetylcysteine and theophylline may be able to prevent the decline of renal function after contrast exposure. This review provides an update on the recent studies in this subject as well as a critical analysis on how available evidence could be translated to daily clinical practice.
Export Options
About this article
Cite this article as:
Fung W.H. Jeffrey, Szeto C. Cheuk, Kum C.C. Leo and Yu M. Cheuk, Prevention of Contrast Induced Nephropathy, Current Drug Therapy 2007; 2 (1) . https://dx.doi.org/10.2174/157488507779422365
DOI https://dx.doi.org/10.2174/157488507779422365 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Effect of Adult and Pediatric Cardiopulmonary Bypass on Pharmacokinetic and Pharmacodynamic Parameters
Current Clinical Pharmacology Levosimendan: A New Inodilatory Drug for the Treatment of Decompensated Heart Failure
Current Pharmaceutical Design Inflammatory Biomarkers in Chronic Kidney Disease: A Review
Recent Patents on Biomarkers Endocannabinoids and Their Receptors: Physiology, Pathology and Pharmacology
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Effect on Serum Uric Acid Levels of Drugs Prescribed for Indications other than Treating Hyperuricaemia
Current Pharmaceutical Design Safety of Canagliflozin in Patients with Type 2 Diabetes
Current Drug Safety Coagulation and Sepsis
Endocrine, Metabolic & Immune Disorders - Drug Targets Monoclonal Antibodies as Cancer Therapeutics
Recent Patents on Biotechnology Putative Role for Apelin in Pressure/Volume Homeostasis and Cardiovascular Disease
Cardiovascular & Hematological Agents in Medicinal Chemistry Association Between Heart Rate Variability and Parkinson’s Disease: A Meta-analysis
Current Pharmaceutical Design Diverse Thiophenes as Scaffolds in Anti-cancer Drug Development: A Concise Review
Mini-Reviews in Medicinal Chemistry Unfolded Protein Response and PERK Kinase as a New Therapeutic Target in the Pathogenesis of Alzheimer’s Disease
Current Medicinal Chemistry Simultaneous Determination of Cytochrome P450 Oxidation Capacity in Humans: A Review on the Phenotyping Cocktail Approach
Current Pharmaceutical Biotechnology Pharmacological Therapy in Children with Atrioventricular Reentry: Which Drug?
Current Pharmaceutical Design CB Receptor Ligands from Plants
Current Topics in Medicinal Chemistry The Use of Biomarkers for Assessing HAART-Associated Renal Toxicity in HIV-Infected Patients
Current HIV Research Pharmacokinetic-Pharmacodynamic Modeling of Antihypertensive Drugs: From Basic Research to Clinical Practice
Current Hypertension Reviews Mas Receptor Agonists as Novel Antihypertensive Agents
Current Hypertension Reviews Effects of Flavonoids in Experimental Models of Arterial Hypertension
Current Topics in Medicinal Chemistry Potential Implications of Angiotensin-converting Enzyme 2 Blockades on Neuroinflammation in SARS-CoV-2 Infection
Current Drug Targets